These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17172046)

  • 1. [The application and research advances of Brucella vaccines].
    Ding JB; Mao KR; Cheng JS; Dai ZH; Jiang YW
    Wei Sheng Wu Xue Bao; 2006 Oct; 46(5):856-9. PubMed ID: 17172046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.
    Vemulapalli R; Contreras A; Sanakkayala N; Sriranganathan N; Boyle SM; Schurig GG
    Vet Microbiol; 2004 Sep; 102(3-4):237-45. PubMed ID: 15327798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
    Winter AJ; Schurig GG; Boyle SM; Sriranganathan N; Bevins JS; Enright FM; Elzer PH; Kopec JD
    Am J Vet Res; 1996 May; 57(5):677-83. PubMed ID: 8723881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants.
    Grilló MJ; Manterola L; de Miguel MJ; Muñoz PM; Blasco JM; Moriyón I; López-Goñi I
    Vaccine; 2006 Apr; 24(15):2910-6. PubMed ID: 16439039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rough vaccines in animal brucellosis: structural and genetic basis and present status.
    Moriyón I; Grilló MJ; Monreal D; González D; Marín C; López-Goñi I; Mainar-Jaime RC; Moreno E; Blasco JM
    Vet Res; 2004; 35(1):1-38. PubMed ID: 15099501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep.
    Jacques I; Verger JM; Laroucau K; Grayon M; Vizcaino N; Peix A; Cortade F; Carreras F; Guilloteau LA
    Vaccine; 2007 Jan; 25(5):794-805. PubMed ID: 17070627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced cerebral infection of Neospora caninum in BALB/c mice vaccinated with recombinant Brucella abortus RB51 strains expressing N. caninum SRS2 and GRA7 proteins.
    Vemulapalli R; Sanakkayala N; Gulani J; Schurig GG; Boyle SM; Lindsay DS; Sriranganathan N
    Vet Parasitol; 2007 Sep; 148(3-4):219-30. PubMed ID: 17651896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brucella suis S2, brucella melitensis Rev. 1 and Brucella abortus S19 living vaccines: residual virulence and immunity induced against three Brucella species challenge strains in mice.
    Bosseray N; Plommet M
    Vaccine; 1990 Oct; 8(5):462-8. PubMed ID: 2123586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
    Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
    Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination.
    Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA
    Vaccine; 2007 May; 25(22):4437-46. PubMed ID: 17442465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ability of Brucella abortus rough vaccine strains to elicit DC and innate immunity in lung using a murine respiratory model.
    Surendran N; Zimmerman K; Seleem MN; Sriranganathan N; Boyle SM; Hiltbold EM; Lawler H; Heid B; Witonsky SG
    Vaccine; 2010 Oct; 28(43):7009-15. PubMed ID: 20727395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serologic responses, biosafety and clearance of four dosages of Brucella abortus strain RB51 in 6-10 months old water buffalo (Bubalus bubalis).
    Diptee MD; Adesiyun AA; Asgarali Z; Campbell M; Adone R
    Vet Immunol Immunopathol; 2006 Jan; 109(1-2):43-55. PubMed ID: 16112746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of formyltransferase (wbkC) gene generates a Brucella abortus rough strain that is attenuated in macrophages and in mice.
    Lacerda TL; Cardoso PG; Augusto de Almeida L; Camargo IL; Afonso DA; Trant CC; Macedo GC; Campos E; Cravero SL; Salcedo SP; Gorvel JP; Oliveira SC
    Vaccine; 2010 Aug; 28(34):5627-34. PubMed ID: 20580469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duplex PCR for differentiation of the vaccine strain Brucella suis S2 and B. suis biovar 1 from other strains of Brucella spp.
    Nan W; Tan P; Wang Y; Xu Z; Mao K; Peng D; Chen Y
    Vet J; 2014 Sep; 201(3):427-8. PubMed ID: 25011712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections.
    Adone R; Francia M; Ciuchini F
    Vaccine; 2008 Sep; 26(38):4913-7. PubMed ID: 18675869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of mice from Brucella infection by immunization with attenuated Salmonella enterica serovar typhimurium expressing A L7/L12 and BLS fusion antigen of Brucella.
    Zhao Z; Li M; Luo D; Xing L; Wu S; Duan Y; Yang P; Wang X
    Vaccine; 2009 Aug; 27(38):5214-9. PubMed ID: 19596411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human exposure to Brucella abortus strain RB51--Kansas, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1998 Mar; 47(9):172-5. PubMed ID: 9518281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51.
    Ashford DA; di Pietra J; Lingappa J; Woods C; Noll H; Neville B; Weyant R; Bragg SL; Spiegel RA; Tappero J; Perkins BA
    Vaccine; 2004 Sep; 22(25-26):3435-9. PubMed ID: 15308369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual virulence and immunogenicity of CGV26 and CGV2631 B. melitensis Rev. 1 deletion mutant strains in sheep after subcutaneous or conjunctival vaccination.
    Guilloteau LA; Laroucau K; Olivier M; Grillo MJ; Marin CM; Verger JM; Blasco JM
    Vaccine; 2006 Apr; 24(17):3461-8. PubMed ID: 16519974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of vertical transmission of Neospora caninum in C57BL/6 mice vaccinated with Brucella abortus strain RB51 expressing N. caninum protective antigens.
    Ramamoorthy S; Sanakkayala N; Vemulapalli R; Jain N; Lindsay DS; Schurig GS; Boyle SM; Sriranganathan N
    Int J Parasitol; 2007 Nov; 37(13):1531-8. PubMed ID: 17575983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.